What is Tepezza and how is it administered?
Tepezza (teprotumumab-trbw) is an infusion therapy used to treat thyroid eye disease (TED), a rare autoimmune condition that affects the eyes. It works by targeting the insulin-like growth factor 1 receptor (IGF-1R), which plays a role in the inflammation and tissue remodeling characteristic of TED [1]. The treatment is administered intravenously, meaning it is given through a needle inserted into a vein [2].
How often are Tepezza infusions given and for how long?
The standard course of Tepezza treatment involves a total of six infusions over approximately 20 weeks. Patients receive an infusion every three weeks [1]. Each infusion is given at a specific dosage: the first dose is 10 mg/kg, followed by seven doses of 3 mg/kg [2].
What is the cost of Tepezza treatment?
The cost of Tepezza can be substantial. For example, one report indicates that a single infusion could cost around $27,000. This means that a full course of treatment, consisting of six infusions, could potentially exceed $160,000 [3]. Patients may be eligible for financial assistance programs offered by the manufacturer or through other third-party programs to help offset these costs [4].
When does Tepezza's patent protection expire?
Patent protection for Tepezza is a critical factor for its market exclusivity. According to DrugPatentWatch.com, the earliest projected expiration date for a key patent covering Tepezza is in 2037. However, the patent landscape can be complex, with multiple patents and potential for extensions or challenges that could alter these timelines [5].
Can biosimilars of Tepezza enter the market before patent expiry?
The development and approval of biosimilars for biologic drugs like Tepezza are subject to specific regulatory pathways and patent protections. Biosimilars are highly similar to the reference biologic product and aim to offer a more affordable alternative. However, biosimilar entry is typically dependent on the expiry of relevant patents and any associated exclusivities. As Tepezza's patents are expected to remain in force for several years, the market is currently protected from biosimilar competition [5].
What are the potential side effects of Tepezza?
Like any medication, Tepezza can cause side effects. Common adverse reactions reported by patients include muscle spasms, nausea, diarrhea, hair loss, decreased appetite, dry eye, and headache. More serious side effects, though less common, have also been observed [1]. Patients are encouraged to discuss any concerns about potential side effects with their healthcare provider.
What clinical data supports Tepezza's use for thyroid eye disease?
Clinical trials have demonstrated Tepezza's effectiveness in treating moderate to severe TED. Studies have shown that Tepezza can significantly reduce proptosis (bulging of the eyes), improve diplopia (double vision), and alleviate other symptoms of TED. For instance, in one key clinical trial, a significant proportion of patients treated with Tepezza experienced a reduction in eye muscle dysfunction and improvement in quality of life compared to placebo [1].
Are there alternative treatments for thyroid eye disease?
While Tepezza is a significant advancement, other treatment options for TED exist, depending on the severity and specific symptoms. These can include corticosteroids for inflammation, orbital radiation therapy, and surgery to address eye muscle problems or decompress the orbit. In some cases, management of underlying thyroid dysfunction is also crucial [6].
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761162s003lbl.pdf
2. https://www.tepezza.com/
3. https://www.fiercepharma.com/drugs/horizon-therapeutics-tepezza-tops-2-billion-annual-sales-eye-disease-drug-could-become-blockbuster
4. https://www.takeda.com/en-us/patients-and-caregivers/patient-assistance/
5. https://drugpatentwatch.com/
6. https://www.mayoclinic.org/diseases-conditions/thyroid-eye-disease/diagnosis-treatment/drc-20378381